New scan could spot hidden cancers

NCT ID NCT06386653

Completed Diagnosis Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 study tested a new radioactive imaging agent called [123I]I-DARPIN-Ec1 in 10 people with lung or ovarian cancer. The goal was to see how the agent spreads in the body and whether it can help spot tumors on SPECT scans. Researchers compared the new scan results with standard imaging like CT or MRI to check if it could improve cancer detection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [123I]I-DARPIN-Ec1 injection
What this could lead to: If successful, this could lead to a more precise imaging method to detect and monitor lung and ovarian cancers.
What could go wrong: This is a very early Phase 1 study with only 10 participants, so results may not apply broadly. The imaging agent's safety and effectiveness are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER OVARIAN CANCER

Contacts and locations

Locations

TomskNRMC

Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.